Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2022 · 10-Q
Revenue—
Net Income-$1.32M-$1.32MN/M vs Q1 2021 EPS Diluted-$0.01-$0.01N/M vs Q1 2021 Operating Income-$1,110,349N/M Operating Cash Flow-$599,545N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
ended Nov 30, 2021 · filed Jan 13, 2022 · 44 d after period end